LivaNova PLC: Director Departs, New Officers Elected

Ticker: LIVN · Form: 8-K · Filed: 2025-09-04T00:00:00.000Z

Sentiment: neutral

Topics: director-departure, officer-appointment, governance

Related Tickers: LIVN

TL;DR

LivaNova director Patrick Lynch out, new execs in. Board shakeup incoming.

AI Summary

LivaNova PLC announced on September 3, 2025, the departure of Director Patrick J. Lynch. The company also reported on the election of new directors and the appointment of certain officers, along with details on compensatory arrangements for these officers. The filing was made on September 4, 2025.

Why It Matters

Changes in board composition and executive appointments can signal shifts in company strategy or governance.

Risk Assessment

Risk Level: medium — Director departures and executive appointments can indicate internal changes that may affect future performance.

Key Players & Entities

FAQ

Who is the departing director?

Patrick J. Lynch is the departing director.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is September 3, 2025.

What is the filing date of this 8-K?

This 8-K was filed on September 4, 2025.

What items are covered in this 8-K filing?

This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.

What is LivaNova PLC's principal executive office address?

LivaNova PLC's principal executive offices are located at 20 Eastbourne Terrace, London, W2 6LG, United Kingdom.

From the Filing

0001639691-25-000120.txt : 20250904 0001639691-25-000120.hdr.sgml : 20250904 20250904090705 ACCESSION NUMBER: 0001639691-25-000120 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250903 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250904 DATE AS OF CHANGE: 20250904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LivaNova PLC CENTRAL INDEX KEY: 0001639691 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 981268150 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37599 FILM NUMBER: 251292025 BUSINESS ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG BUSINESS PHONE: 4402033250662 MAIL ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Plc DATE OF NAME CHANGE: 20150420 FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Ltd DATE OF NAME CHANGE: 20150415 8-K 1 livn-20250903.htm 8-K livn-20250903 LIVANOVA PLC 0001639691 false 0001639691 2025-09-03 2025-09-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction  of Incorporation) (Commission File Number) (IRS Employer Identification No.) 20 Eastbourne Terrace London , W2 6LG United Kingdom (Address of Principal Executive Offices) + 44 20 33250660 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name on each exchange on which registered Ordinary Shares - £1.00 par value per share LIVN NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On September 3, 2025, the Board of Directors (the “Board”) of LivaNova PLC (the “Company”) appointed Donald Zurbay to the Board and as a member of the Audit and Compliance Committee of the Board. His term begins September 4, 2025. Mr. Zurbay has served in numerous key leadership positions at different healthcare companies over the pas

View on Read The Filing